Francisco G. La Rosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Francisco G. La Rosa has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Amy K. Darke
Fred Hutchinson Cancer Research Center, Seattle, WA
2 shared publications Charles A. Coltman
2 shared publications- Howard L. Parnes
Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland
2 shared publications - Ian Murchie Thompson
Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, Texas
2 shared publications - Kedar N. Prasad
Engage Global Inc., San Rafael, California, USA
2 shared publications - Leslie G. Ford
Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland
2 shared publications
Latest Publications
- Open Access
- 7 January 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (1) , e265657
Rosai-Dorfman disease mimicking testicular malignancy in a patient with marginal zone lymphoma of the lung
Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing extranodal manifestations in nearly 50% of cases, particularly in the skin and upper respiratory tract. A hallmark histological feature is emperipolesis—large CD68+ and S100+ histiocytes containing intact inflammatory cells. We report a unique case of bilateral testicular RDD in a man with prior extranodal marginal zone lymphoma of the lungs. Three years after lymphoma remission, he presented with bilateral testicular enlargement. Ultrasound and positron emission tomography/CT showed diffuse hypoechoic parenchyma with metabolic activity suggestive of malignancy. Bilateral orchiectomy revealed tan-yellow, fleshy masses infiltrating the testicular parenchyma. Histology confirmed RDD with emperipolesis and S100+/CD68+/CD1a− phenotype. Testicular RDD is extremely uncommon, with only ~15 cases described to date, and its association with haematological malignancy remains poorly understood. Recognition of this entity is essential to avoid unnecessary oncological treatment.
- 7 January 2026
- Published by BMJ in BMJ Case Reports
- Vol. 19 (1) , e265657
Open AccessRosai-Dorfman disease mimicking testicular malignancy in a patient with marginal zone lymphoma of the lung
Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing extranodal manifestations in nearly 50% of cases, particularly in the skin and upper respiratory tract. A hallmark histological feature is emperipolesis—large CD68+ and S100+ histiocytes containing intact inflammatory cells. We report a unique case of bilateral testicular RDD in a man with prior extranodal marginal zone lymphoma of the lungs. Three years after lymphoma remission, he presented with bilateral testicular enlargement. Ultrasound and positron emission tomography/CT showed diffuse hypoechoic parenchyma with metabolic activity suggestive of malignancy. Bilateral orchiectomy revealed tan-yellow, fleshy masses infiltrating the testicular parenchyma. Histology confirmed RDD with emperipolesis and S100+/CD68+/CD1a− phenotype. Testicular RDD is extremely uncommon, with only ~15 cases described to date, and its association with haematological malignancy remains poorly understood. Recognition of this entity is essential to avoid unnecessary oncological treatment.
- Open Access
- 1 January 2025
- Published by XMLink in Immune Network
- Vol. 25 (4)
Pathotype-Specific Expression of Granzyme-Perforin Pathway Genes and Their Association With Clinical Disease Activity in Early Rheumatoid Arthritis and in a Randomized Clinical Trial
La Rosa FG, et al. Immune Netw. 2025 Jun;25(4):e25. https://doi.org/10.4110/in.2025.25.e25
- 1 January 2025
- Published by XMLink in Immune Network
- Vol. 25 (4)
Open AccessPathotype-Specific Expression of Granzyme-Perforin Pathway Genes and Their Association With Clinical Disease Activity in Early Rheumatoid Arthritis and in a Randomized Clinical Trial
La Rosa FG, et al. Immune Netw. 2025 Jun;25(4):e25. https://doi.org/10.4110/in.2025.25.e25
- 1 December 2024
- Published by Springer Nature
- p. 219-240
Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize, and Treat the mpMRI Invisible Lesion
- 1 December 2024
- Published by Springer Nature
- p. 219-240
Using Multicore, Transperineal Prostate Mapping Biopsy to Detect, Localize, and Treat the mpMRI Invisible Lesion
- Open Access
- 1 January 2021
- Published by XMLink in Immune Network
- Vol. 21 (6) , e45
A Potential New Mouse Model of Axial Spondyloarthritis Involving the Complement System
Holers VM, et al. Immune Netw. 2021 Dec;21(6):e45. https://doi.org/10.4110/in.2021.21.e45
- 1 January 2021
- Published by XMLink in Immune Network
- Vol. 21 (6) , e45
Open AccessA Potential New Mouse Model of Axial Spondyloarthritis Involving the Complement System
Holers VM, et al. Immune Netw. 2021 Dec;21(6):e45. https://doi.org/10.4110/in.2021.21.e45
- Open Access
- 1 January 2021
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 22 (10) , 1650-1657
Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors
Green DB, et al. Korean J Radiol. 2021 Jul;22:e97. https://doi.org/10.3348/kjr.2020.1391
- 1 January 2021
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 22 (10) , 1650-1657
Open AccessMetastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors
Green DB, et al. Korean J Radiol. 2021 Jul;22:e97. https://doi.org/10.3348/kjr.2020.1391
- 1 January 2000
- Published by Springer Nature in In Vitro Cellular & Developmental Biology - Animal
- Vol. 36 (2) , 81-7
RELATIVE SENSITIVITY OF UNDIFFERENTIATED AND CYCLIC ADENOSINE 3′,5′-MONOPHOSPHATE–INDUCED DIFFERENTIATED NEUROBLASTOMA CELLS TO CYCLOSPORIN A: POTENTIAL ROLE OF β-AMYLOID AND UBIQUITIN IN NEUROTOXICITY
Cyclosporin A is routinely used in transplant therapy following allogeneic or xenogeneic tissue transplantation to prevent rejection. This immunosuppressive drug is also neurotoxic; however, its mechanisms of action for neurotoxicity are poorly understood. Undifferentiated and cyclic adenosine 3',5'-monophosphate (cAMP)-induced differentiated neuroblastoma (NB) cells were used as an experimental model to study the toxicity of cyclosporin A. Results showed that cyclosporin A promoted the outgrowth of neurites and inhibited the growth of undifferentiated NB cells. When cyclosporin A was added simultaneously with RO20-1724, an inhibitor of cyclic nucleotide phosphodiesterase, or with prostaglandin E1, a stimulator of adenylate cyclase, it markedly enhanced the growth inhibitory and differentiation effects of these cAMP-stimulating agents. In addition, cyclosporin A added to cAMP-induced differentiated NB cells caused dose-dependent degeneration of these cells as evidenced by the vacuolization of cytoplasm and the fragmentation of nuclear and cytoplasmic materials; however, neurites remained intact. Cyclosporin A alone did not alter the intensity of cell immunostaining for ubiquitin or beta-amyloid peptide (amino acids 1-14) (Abeta1-14); however, it enhanced the intensity of staining for both ubiquitin and Abeta in cells that were treated with cAMP-stimulating agents. The intensity of staining of amyloid precursor protein (amino acids 44-63) (APP44-66) did not change in any treated group, suggesting that the increase in Abeta staining is due to increased processing of APP to Abeta. We propose that one of the mechanisms of cyclosporin A-induced neurotoxicity involves increased levels of Abeta and ubiquitin.
- 1 January 2000
- Published by Springer Nature in In Vitro Cellular & Developmental Biology - Animal
- Vol. 36 (2) , 81-7
RELATIVE SENSITIVITY OF UNDIFFERENTIATED AND CYCLIC ADENOSINE 3′,5′-MONOPHOSPHATE–INDUCED DIFFERENTIATED NEUROBLASTOMA CELLS TO CYCLOSPORIN A: POTENTIAL ROLE OF β-AMYLOID AND UBIQUITIN IN NEUROTOXICITY
Cyclosporin A is routinely used in transplant therapy following allogeneic or xenogeneic tissue transplantation to prevent rejection. This immunosuppressive drug is also neurotoxic; however, its mechanisms of action for neurotoxicity are poorly understood. Undifferentiated and cyclic adenosine 3',5'-monophosphate (cAMP)-induced differentiated neuroblastoma (NB) cells were used as an experimental model to study the toxicity of cyclosporin A. Results showed that cyclosporin A promoted the outgrowth of neurites and inhibited the growth of undifferentiated NB cells. When cyclosporin A was added simultaneously with RO20-1724, an inhibitor of cyclic nucleotide phosphodiesterase, or with prostaglandin E1, a stimulator of adenylate cyclase, it markedly enhanced the growth inhibitory and differentiation effects of these cAMP-stimulating agents. In addition, cyclosporin A added to cAMP-induced differentiated NB cells caused dose-dependent degeneration of these cells as evidenced by the vacuolization of cytoplasm and the fragmentation of nuclear and cytoplasmic materials; however, neurites remained intact. Cyclosporin A alone did not alter the intensity of cell immunostaining for ubiquitin or beta-amyloid peptide (amino acids 1-14) (Abeta1-14); however, it enhanced the intensity of staining for both ubiquitin and Abeta in cells that were treated with cAMP-stimulating agents. The intensity of staining of amyloid precursor protein (amino acids 44-63) (APP44-66) did not change in any treated group, suggesting that the increase in Abeta staining is due to increased processing of APP to Abeta. We propose that one of the mechanisms of cyclosporin A-induced neurotoxicity involves increased levels of Abeta and ubiquitin.
- 1 January 1994
- Published by SAGE Publications in Restorative Neurology and Neuroscience
- Vol. 7 (1) , 13-19
Production of terminally differentiated neuroblastoma cells in culture
The use of fetal central nervous system (CNS) tissue in neural transplants has ethical, availability and some biological limitations. In order to overcome these problems, homogeneous populations of specific neurons in vitro should be established. Transformed nerve cells such as neuroblastoma cells (NBP2) in culture can serve as one of the sources of donor neurons in neural transplants provided they can be induced to differentiate terminally. This study showed that treatment of murine neuroblastoma (NBP2) cells with 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (R020-1724, an inhibitor of cyclic nucleotide phosphodiesterase), and β-carotene for a period of 3 days followed by X-irradiation with 20 Gy or above produced 100% terminally differentiated cells. These differentiated NB cells had long and extensive neurites, contained elevated levels of tyrosine hydroxylase (TH) activity and very low levels of MHC class I and II antigens, and were non-tumorigenic. The viability of differentiated NB cells when determined on the criteria of attachment efficiency, re-extension of neurites and presence of TH after replating was only 9%. This was in contrast to the trypan blue exclusion technique which showed that over 90% of differentiated NB cells in culture were viable.
- 1 January 1994
- Published by SAGE Publications in Restorative Neurology and Neuroscience
- Vol. 7 (1) , 13-19
Production of terminally differentiated neuroblastoma cells in culture
The use of fetal central nervous system (CNS) tissue in neural transplants has ethical, availability and some biological limitations. In order to overcome these problems, homogeneous populations of specific neurons in vitro should be established. Transformed nerve cells such as neuroblastoma cells (NBP2) in culture can serve as one of the sources of donor neurons in neural transplants provided they can be induced to differentiate terminally. This study showed that treatment of murine neuroblastoma (NBP2) cells with 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (R020-1724, an inhibitor of cyclic nucleotide phosphodiesterase), and β-carotene for a period of 3 days followed by X-irradiation with 20 Gy or above produced 100% terminally differentiated cells. These differentiated NB cells had long and extensive neurites, contained elevated levels of tyrosine hydroxylase (TH) activity and very low levels of MHC class I and II antigens, and were non-tumorigenic. The viability of differentiated NB cells when determined on the criteria of attachment efficiency, re-extension of neurites and presence of TH after replating was only 9%. This was in contrast to the trypan blue exclusion technique which showed that over 90% of differentiated NB cells in culture were viable.